Group 1 - The core viewpoint of the article highlights the recent stock performance of Zhengye Biological (ZYBT), which saw an increase of 4.91% to $5.56 per share, with a total market capitalization of $263 million as of August 5 [1] - Financial data indicates that Zhengye Biological's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, representing a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is reported at 11.31 million RMB, reflecting a significant year-on-year decline of 64.04% [1] Group 2 - Zhengye Biological Holdings Limited is registered in the Cayman Islands and primarily operates through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨4.91%，报5.56美元/股，总市值2.63亿美元